Methods. During the period 1997-2002, a total of 633 HIV-infected patients were tested for HBV serological markers at baseline, including hepatitis B surface antigen (HBsAg), antibody to HBsAg (anti-HBs ), antibody to hepatitis B core antigen (anti-HBc), hepatitis C virus (HCV) antibody (anti-HCV) antibody, HCV RNA level, and HBV DNA level, all of which were retested at least 1 year apart. Medical records were reviewed to identify clinical characteristics associated with evolution of these serological markers.
antibody to hepatitis B core antigen (anti-HBc) and persistent chronic HBs antigenemia have been observed more often in HIV-infected patients because of impaired host immunity against HBV [5, [11] [12] [13] . However, factors associated with evolution of serological markers of HBV in HIV-infected patients receiving HAART remain unclear. With HAART, immune reconstitution may increase the frequency of HBV reactivation in hepatitis B surface antigen (HBsAg) carriers or the development of antibody to HBsAg (anti-HBs) [14, 15] . Previous studies that assessed the evolution of HBV serological patterns in HIV-infected patients were limited by the inclusion of only injection drug users [5] or patients who were not receiving HAART [6] [7] [8] [9] [10] or by a small number of patients in an area with a low prevalence of HBV infection [11] . In this longitudinal follow-up study, we aimed to assess the evolution of HBV serological markers in HIV-infected patients receiving HAART in Taiwan, where the prevalence of HBV coinfection in HIVinfected patients is much higher than that in Western countries (22% vs. 6%-10%) [2, 3] .
PATIENTS AND METHODS
Patients. During the period from 1 January 1997 through 31 December, 2002, HIV-infected patients who were antiretroviral naive and underwent serological testing for HBV infection before the initiation of HAART at the National Taiwan University Hospital (Taipei) were eligible for this longitudinal follow-up study. Patients who underwent repeated HBV serological testing in 2003 and 2004, with tests taken у1 year apart, were included in the analysis. To better understand the evolution of HBV serological markers, patients who had a known history of HBV vaccination were excluded-especially patients born after 1984, when universal HBV vaccination was launched in Taiwan [16] .
Determination of HBV and hepatitis C virus (HCV) serological markers and data collection. Demographic, clinical, serological, and virological data were recorded using a standardized data collection form. Patients without any HBV serological markers noted in consecutive tests were encouraged to undergo HBV vaccination. At the end of the study, 20 of 35 patients without any HBV serological markers subsequently received HBV vaccine and, therefore, were censored on the date of HBV vaccination. HBsAg, anti-HBs, and anti-HBc were determined using an EIA (Abbott Laboratories). All HBV serological tests were repeated. If discrepancies of results occurred between the 2 tests, a third test was performed. Antibodies to HCV (anti-HCV) were determined using a third-generation EIA (AxSYM HCV III; Abbott Laboratories).
Quantification of HBV DNA level, HIV RNA level, and CD4 lymphocyte count. HBV DNA was extracted from 200 mL of serum obtained from all patients at enrollment and from patients who tested positive for HBs antigenemia or isolated antiHBc in subsequent tests (High Pure Viral Nucleic Acid Kit; Roche Molecular Biochemicals). The HBV DNA level was quantified using a real-time PCR with the LighterCycler instrument (Roche Molecular Biochemicals), in accordance with the manufacturer's instructions. The detection limit of HBV DNA was estimated to be 10 3 copies/mL. The plasma HIV RNA level was determined using a commercial kit (Roche Amplicor, version 1.5), which has a detection limit of 400 copies/mL (2.60 log 10 copies/mL). CD4 cell counts were determined using FACFlow (BD FACS Calibur; Becton Dickinson). Both the plasma HIV RNA level and the CD4 cell count were determined at enrollment, 1 month after initiation of HAART, and every 3-4 months thereafter.
Definitions of isolated anti-HBc, virological and immunologic responses to antiretroviral therapy, and progression of HIV infection. Isolated anti-HBc was defined as an instance in which blood samples tested positive for anti-HBc but negative for both HBsAg and anti-HBs. Virological response to HAART was assessed by the proportion of patients who achieved an undetectable plasma HIV RNA level at 12 months, 24 months, and the last available assessment of the plasma HIV RNA level data. The analysis was performed on the basis of the on-treat principle. Virological failure was defined as failure to achieve an undetectable plasma HIV RNA level 6 months after the initiation of HAART or as a repeatedly detectable plasma HIV RNA level after initial suppression. Immunologic response was assessed by the increase in the CD4 cell count from baseline at 12 months, 24 months, and the last available assessment of CD4 cell count data and by the proportion of patients who achieved an increase in the CD4 cell count of 100 and 200 cells/mL or more during the follow-up period. Progression of HIV infection was defined as a relapse or new occurrence of an AIDS-defining opportunistic illness [17] 1 month after the initiation of HAART.
Statistical analysis. All statistical analyses were performed using SPSS software, version 13.0 (SPSS). Categorical variables were compared using the x 2 test or Fisher's exact test, and noncategorical variables were compared using the Wilcoxon rank sum test. Point estimation for Poisson distribution was used for estimating the incidence and 95% CIs of changes of HBV serological markers. Multivariate analysis with the multiple logistic regression method and a stepwise forward and backward model was used to assess the impact of the variables (e.g., age, sex, risk behavior for HIV transmission, HCV coinfection, baseline CD4 cell count and plasma HIV RNA level, presence of AIDS-related diseases, use and duration of lamivudine and HAART, and CD4 cell count increase and undetectable plasma HIV RNA level after initiation of HAART) on the persistence or subsequent development of anti-HBs among patients with HBsAg, anti-HBs, and isolated anti-HBc detected at baseline. ORs and 95% CIs were calculated for logistic regression analyses. All tests were 2-tailed, and P values !.05 were considered to be statistically significant. Survival probabilities were estimated by the Kaplan-Meier method. The duration of observation for each patient was estimated from the date of the first HBV serological test to the date of the last HBV serological test. Equality of survival distributions was evaluated by the log-rank test. The duration of survival for patients was estimated from the date of enrollment to death, to last followup visit at this hospital and other designated hospitals in Taiwan, or to the end of this study (31 December 2005).
RESULTS
Characteristics of the population studied. During the period from January 1997 through December 2002, a total of 975 patients sought care for HIV infection at National Taiwan University Hospital; 342 patients were excluded from the study (figure 1), and 633 patients (583 male and 50 female patients) were enrolled. There were no significant differences in demographic characteristics and baseline clinical, virological, and immunologic data between patients who were enrolled and those who were excluded (data not shown anti-HBs present, in 13 patients (7.3%) with isolated anti-HBc present, and in 3 patients (4.6%) without any HBV markers.
Compared with patients who did not have any HBV markers, there were no significant baseline differences in terms of age, risk for HIV transmission, HCV seropositivity, and duration of HAART and lamivudine use in patients in the other 3 groups (table 1) . However, there were more male patients who had any HBV serological markers ( -.08), patients with iso-P p .005 lated anti-HBc present had a greater level of immunosuppression, and patients with HBsAg present were more likely to have detectable HBV DNA ( ). The statistical results were P ! .001 unchanged after we excluded the 3 patients with detectable HBV DNA levels from the group of patients without any markers.
HBV serological markers and patient outcomes. The patients were observed for a median duration of 4.96 years (range, 1.07-7.97 years). After initiation of HAART, patients with HBsAg present and those with isolated anti-HBc present had less robust increases in the CD4 cell count, compared with patients who did not have any HBV serological markers (at 24 months after initiation of HAART, the values were 140 and 117 cells/mL vs. 180 cells/mL, respectively;
and .04, respec-P p .03 tively), and were less likely to achieve an undetectable plasma HIV RNA level (at 24 months after initiation of HAART, the proportions of patients were 69.8% and 75.6% vs. 89.1%, respectively;
and .03, respectively). Moreover, patients P p .006 with HBsAg present were more likely to develop virological failure (42.9% vs. 27.7%;
) and to die (22.7% vs. 7.7%; P p .04 ) than were patients without any HBV serological P p .01 markers.
Evolution of HBV serological markers. A total of 161 patients Of the 65 patients without any HBV markers at baseline, the median follow-up duration was 4.76 years (range, 1.27-7.97 years). Thirty patients (46.2%) without any HBV markers at baseline were later found to be ever exposed to HBV: 4 (6.2%) developed HBsAg, 13 (20%) anti-HBs, and 13 (20%) isolated anti-HBc. The incidence of new HBV infection in HIV-infected patients without any HBV markers at baseline was 9.69 per 100 person-years (95% CI, 6.28-13.30 per 100 person-years).
Outcome analysis of patients with and without changes in serological markers. Among patients with HBsAg present at baseline, the characteristics of 104 patients with persistent HBs antigenemia and 6 patients with subsequent development of anti-HBs were compared. There were no significant differences with regard to age, sex, risk factor for HIV transmission, baseline CD4 cell count and plasma HIV RNA level, increase in the CD4 cell count during HAART, and virological response to HAART between these 2 groups (data not shown).
Among the patients with anti-HBs present at baseline, patients who subsequently lost anti-HBs during HAART had less robust increases in the CD4 cell count after the initiation of HAART, compared with patients who had persistent anti- (table 3) . Twenty-four P p .04 months after the initiation of HAART, an increase in the CD4 cell count of у100 cells/mL was the only independent factor associated with the development of anti-HBs (adjusted OR, 4.65; 95% CI, 1.96-11.02;
). P p .001 Survival estimates among the 4 groups of patients are shown in figure 2A . Patients with detected HBsAg had a shorter duration of survival than did patients in the other 3 groups. Patients with isolated anti-HBc detected at baseline had a shorter duration of survival than did patients with anti-HBs present ( ). Patients who had persistent HBsAg during follow-P p .02 up had a worse duration of survival than did patients who had persistent anti-HBs ( ), those who had persistent isolated P ! .001 anti-HBc ( ), and those who subsequently developed P p .07 anti-HBs ( ) ( figure 2B ). P p .12
DISCUSSION
In this study, the prevalence of any exposure to HBV, which was defined as the presence of any serological marker of HBV infection (89.8%) and as chronic HBV infection (16.4%), in HIV-infected patients was similar to that of other Taiwanese adult populations, in which 90% of persons had exposure to HBV and 15%-20% were chronic carriers of HBV [18] . The higher HBV seroprevalence could be explained by the fact that, in Taiwan, most cases of HBV infection occur during the perinatal period or early childhood, before the implementation of the nationwide HBV vaccination program [18, 19] .
The proportion of the patients in our study who had changes in HBV serological patterns (25.4%) was significantly higher than the proportions reported in other studies (12% and 16%, with median durations of follow-up of 2.2 years and 21 months, respectively) [5, 11] . Such changes of HBV serological markers after initiation of HAART mainly involved anti-HBs development in patients who had isolated anti-HBc and acquisition of HBV infection in those who had no HBV serological markers at baseline (45.3% and 18.6% of the 161 patients with changes of serological markers, respectively). The HBsAg clearance rate respectively. b CD4 cell count and plasma HIV RNA level were available for 232 and 13 patients with persistent anti-HBs and patients with subsequently undetectable antiHBs antibodies, respectively, at 24 months after the initiation of HAART.
among our patients (2.57 cases per 100 person-years) was low, even after immune reconstitution associated with HAART that contained lamivudine. The low HBsAg clearance rate is not surprising, because the overall incidence of HBsAg clearance has been low even in HIV-uninfected HBV-carrying adults [20] . Furthermore, the cumulative resistance rate of HBV to lamivudine is high in HIV-infected patients [21] . Despite recent advances in anti-HBV therapy, the seroconversion rate remains low, regardless of whether the agents are used in combination [22, 23] . Loss of hepatitis B immunity occurs in association with HIV infection [5, 10, 24] . Among HIV-infected patients who were not receiving HAART, loss of anti-HBs occurred in 13%-17% of patients with hemophilia [24] and 28% of men who have sex with men [25] , compared with 0% of HIV-uninfected patients during observation periods of 2 and 3 years. Achieving an undetectable plasma HIV RNA level and greater gains in the CD4 cell count in association with HAART enables HIV-HBV-coinfected patients to achieve HBsAg clearance, anti-HBe seroconversion, and suppression of HBV replication [25] . In this study, 193% of such patients who received HAART continued to have detectable anti-HBs, despite severe immunosuppression; these patients tended to have better virological and immunologic responses to HAART than did patients who subsequently lost anti-HBs. These data suggest that preservation of anti-HBs requires better adherence to HAART to achieve better immune reconstitution.
Our results showed that determination of only HBsAg and anti-HBs data may miss patients who had isolated anti-HBc. In such patients in whom isolated anti-HBc is detected, determination of the HBV DNA level is important to clarify the status of their HBV infection [26, 27] . By determination of the HBV DNA level, we found that occult or window-period HBV infection occurred in 7.3% of the patients in our study who had isolated anti-HBc detected and in 4.6% of patients who did not have any HBV serological markers. The prevalence of occult or window-period HBV infection in our patients was much higher than that (0.6%) in another large cohort study [28] ; this can possibly be attributed to a higher background prevalence of chronic HBV infection in Taiwan and lower baseline CD4 cell counts in our patients (132 vs. 414 cells/mL [28] ). The appropriate treatment for HIV-infected persons who have isolated anti-HBc remains unknown. HBV vaccination may be considered, because a recent study suggested that 160% of patients with isolated anti-HBc developed seroprotective anti-HBs titers [29] . However, determination of the HBV DNA level should be considered, to exclude the possibility of occult HBV infection in patients with isolated anti-HBc (as occurred in 7.3% in our patients) before HBV vaccine is to be administered. Of the patients in our study who did not receive HBV revaccination, 40.8% of those with isolated anti-HBc who achieved better virological and immunologic responses to HAART developed anti-HBs, suggesting that immune reconstitution may restore immunity against HBV.
Among patients without any HBV serological markers, we observed a higher rate of HBV infection (9.69 cases per 100 person-years) than has been observed in other reports (0.2-0.3 cases per 100 person-years) [3] [4] [5] 11] and in a study of HIVuninfected persons in Taiwan [16] . The higher rates of HBV transmission may be associated with low CD4 cell counts and decreased cellular immunity against HBV infection by HIV infection after risky exposure. This finding highlights the importance of vaccination of all HIV-infected patients without HBV markers and of counseling against HBV infection.
There were limitations to our study. First, not all patients received sequential HBV serological tests, and patients with shorter observation periods (i.e., !1 year) were excluded from the study; thus, selection bias could not be avoided, although the characteristics of excluded patients were similar to those of enrolled patients. Second, our population is unique in that most patients with detected HBsAg were chronic HBV carriers since childhood, and the injection drug users and HIV-HCV-coin- Figure 2 . A, Kaplan-Meier survival estimates among patients with hepatitis B surface antigen (HBsAg), antibody to HBsAg (anti-HBs), and isolated antibody to hepatitis B core antigen (anti-HBc) and without hepatitis B virus serological markers at baseline. Patients with HBsAg had shorter durations of survival than did those with anti-HBs, those with isolated anti-HBc, and those without HBV serological markers ( to .001). P ! .001 There were no statistically significant survival differences between patients with anti-HBs and those without any HBV serological markers ( ) or between patients with isolated anti-HBc and those without P p .99 any HBV serological markers ( ). However, patients with isolated P p .16 anti-HBc at baseline had shorter survival durations than did those with anti-HBs ( ). B, Kaplan-Meier survival estimates among patients P p .02 with HBsAg persistence, patients with anti-HBs persistence, patients with isolated anti-HBc who subsequently developed anti-HBs, and patients who had persistent isolated anti-HBc noted in follow-up blood tests. Patients with HBsAg persistence had shorter durations of survival than did those with anti-HBs persistence ( ), those with isolated anti-P ! .001 HBc who subsequently developed anti-HBs ( ), and those with P p .12 persistent isolated anti-HBc ( ). Patients with anti-HBs persistence P p .07 had longer durations of survival than did those with persisted isolated anti-HBc ( ) and those who subsequently developed anti-HBs P p .02 ( ) . P ! .001 fected patients accounted for only a small proportion of the study population. Thus, our findings might not be generalizable to other populations with different epidemiologic and demographic characteristics. Third, attempts to identify factors (e.g., baseline HBV DNA level) associated with changes in HBV serological markers after initiation of lamivudine-containing HAART may be limited by the small numbers of cases in certain groups (tables 2 and 3). Finally, we were not able to completely exclude the possibility that changes in HBV serological markers may have been caused by the variability of serological tests, although we repeated serological tests with each serum sample in our study.
In conclusion, changes in HBV serological markers are not uncommon in a region where HBV infection is endemic, and repeated measurement of HBV markers (including anti-HBc) in patients with HIV infection should be considered. Better virological and immunologic responses to HAART are associated with preservation and development of anti-HBs. HBV vaccination should be routinely advised to patients without any HBV markers.
